| Subject: | FDA Provides Medtronic Recommendations for Inflammatory Masses with Synchromed and IsoMed Implantable Infusion Pumps |
| Category: | Food and Drug Administration (FDA)
|
| Published: | Mon, 9 Jun 2008 - 06:00 am |
| On January 16, 2008, Medtronic notified healthcare professionals about an increased rate of inflammatory masses in patients receiving intrathecal drugs through the company's Synchromed EL, Synchromed II and IsoMed implantable infusion pump systems. The January 16th notice, which also gave patient management and treatment recommendations, was an update to two earlier communications. Please see the StayAlert notice published on February 4, 2008 for additional information on these... The full article is available to StayAlert subscribers. Click here for a free trial subscription. |
|
RESOURCES:
External Links:
|
|
StayAlert! notifies healthcare customers of all federal and regulatory body legislation changes impacting the healthcare industry, including TJC (JCAHO), CDC, CMS, DHHS, FDA, OSHA, OIG and many others. StayAlert! complements this with regulatory implementation action plans. StayAlert! serves as a virtual healthcare department, augmenting traditional employee staffed departments and freeing employees to perform other vital functions. StayAlert! is the only comprehensive clinical and regulatory service providing organizations in the healthcare arena with practical applications to meet complex mandated federal requirements. |
|
